Progenics Pharmaceuticals Inc. (PGNX) Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its position in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 3.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,600 shares of the biotechnology company’s stock after acquiring an additional 1,868 shares during the period. The Manufacturers Life Insurance Company owned about 0.09% of Progenics Pharmaceuticals worth $412,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of PGNX. BlackRock Inc. grew its holdings in shares of Progenics Pharmaceuticals by 149,468.9% in the first quarter. BlackRock Inc. now owns 9,523,053 shares of the biotechnology company’s stock worth $89,897,000 after acquiring an additional 9,516,686 shares during the period. Eagle Asset Management Inc. grew its holdings in shares of Progenics Pharmaceuticals by 50.8% in the second quarter. Eagle Asset Management Inc. now owns 4,012,366 shares of the biotechnology company’s stock worth $27,243,000 after acquiring an additional 1,352,245 shares during the period. Vanguard Group Inc. grew its holdings in shares of Progenics Pharmaceuticals by 46.1% in the first quarter. Vanguard Group Inc. now owns 4,132,770 shares of the biotechnology company’s stock worth $39,013,000 after acquiring an additional 1,304,487 shares during the period. State Street Corp grew its holdings in shares of Progenics Pharmaceuticals by 42.7% in the second quarter. State Street Corp now owns 3,708,788 shares of the biotechnology company’s stock worth $25,186,000 after acquiring an additional 1,110,067 shares during the period. Finally, Numeric Investors LLC bought a new stake in shares of Progenics Pharmaceuticals in the second quarter worth $2,877,000. 84.84% of the stock is owned by institutional investors.

PGNX has been the subject of several research analyst reports. ValuEngine lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Cantor Fitzgerald set a $15.00 target price on Progenics Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Aegis reiterated a “buy” rating and set a $14.00 target price on shares of Progenics Pharmaceuticals in a research report on Tuesday, August 22nd. Needham & Company LLC reiterated a “strong-buy” rating and set a $14.00 target price on shares of Progenics Pharmaceuticals in a research report on Friday, September 1st. Finally, Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. Three equities research analysts have rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $13.20.

Progenics Pharmaceuticals Inc. (PGNX) opened at $5.54 on Wednesday. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.80. Progenics Pharmaceuticals Inc. has a 52-week low of $4.60 and a 52-week high of $11.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The company had revenue of $2.70 million for the quarter, compared to the consensus estimate of $3.58 million. Progenics Pharmaceuticals had a negative return on equity of 67.61% and a negative net margin of 445.81%. Progenics Pharmaceuticals’s quarterly revenue was down 95.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.52 earnings per share. analysts anticipate that Progenics Pharmaceuticals Inc. will post -0.92 earnings per share for the current year.

WARNING: This story was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/29/progenics-pharmaceuticals-inc-pgnx-shares-bought-by-the-manufacturers-life-insurance-company.html.

Progenics Pharmaceuticals Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply